Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 598 | 111 | 481 |
| Samples | 568 | 102 | 461 |
| Peptides | 398 | 66 | 346 |
Function
PRKCG · Protein kinase C gamma
Protein kinase C (PKC) is a family of serine- and threonine-specific protein kinases that can be activated by calcium and second messenger diacylglycerol. PKC family members phosphorylate a wide variety of protein targets and are known to be involved in diverse cellular signaling pathways. PKC also serve as major receptors for phorbol esters, a class of tumor promoters. Each member of the PKC family has a specific expression profile and is believed to play distinct roles in cells. The protein encoded by this gene is one of the PKC family members. This protein kinase is expressed solely in the brain and spinal cord and its localization is restricted to neurons. It has been demonstrated that several neuronal functions, including long term potentiation (LTP) and long term depression (LTD), specifically require this kinase. Knockout studies in mice also suggest that this kinase may be involved in neuropathic pain development. Defects in this protein have been associated with neurodegenerative disorder spinocerebellar ataxia-14 (SCA14). Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2015].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000263431 | P05129 | 598 | 398 |
Gene Properties
Recurrent Mutations
All 398 amino-acid changes on canonical ENST00000263431 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PRKCG · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PRKCG – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Endometrial Carcinoma | 15/42 36% | 15/612 2% |
| Squamous Cell Lung Carcinoma | 5/57 9% | 24/810 3% |
| Hodgkins Lymphoma | 3/16 19% | 1/122 1% |
| Melanoma | 4/210 2% | 57/1899 3% |
| Non-Small Cell Lung Carcinoma | 14/304 5% | 35/1390 3% |
| Neuroendocrine Tumour | 8/154 5% | 10/577 2% |
| Colorectal Carcinoma | 11/143 8% | 60/3239 2% |
| Other Solid Cancers | 2/94 2% | 31/1515 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Retinoblastoma | 0/27 0% | 1/30 3% |
| Small Cell Lung Carcinoma | 0/9 0% | 13/752 2% |
| Gastric Carcinoma | 0/74 0% | 29/1809 2% |
| Cervical Carcinoma | 2/35 6% | 4/422 1% |
| Ovarian Carcinoma | 8/109 7% | 6/998 1% |
| Head and Neck Carcinoma | 2/85 2% | 18/1574 1% |
| Non-Cancerous | 0/104 0% | 11/830 1% |
| Bladder Carcinoma | 3/58 5% | 9/956 1% |
| Plasma Cell Myeloma | 1/44 2% | 3/305 1% |
| Chondrosarcoma | 1/14 7% | 0/75 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 22/2550 1% |
| Hepatocellular Carcinoma | 0/46 0% | 19/2210 1% |
| Pancreatic Carcinoma | 4/89 4% | 10/1611 1% |
| Biliary Tract Carcinoma | 0/54 0% | 8/950 1% |
| Meningioma | 0/3 0% | 2/252 1% |
| Glioma | 1/52 2% | 14/2127 1% |
| Thyroid Gland Carcinoma | 2/45 4% | 9/1592 1% |
| Other Sarcomas | 0/69 0% | 5/699 1% |
| Breast Carcinoma | 1/144 1% | 18/3264 1% |
| Kidney Carcinoma | 2/85 2% | 8/1862 0% |
Mutation Distribution
Where PRKCG is mutated · all tissues, split by cell line vs tissue
How many mutations in PRKCG were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 598 mutations in PRKCG
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|